SCHEMBL6411271

SCHEMBL6411271

CN1C(=O)c2ccccc2C(C(=O)Nc2cc[nH]n2)C1c1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.59
MAPT P10636 2/20 0.59
KDM4E B2RXH2 2/20 0.59
TSHR P16473 5/20 0.58
GAA P10253 1/20 0.54
HSD17B10 Q99714 3/20 0.54
LMNA P02545 1/20 0.54
FFAR1 O14842 1/20 0.53
NPC1 O15118 1/20 0.52
HTT P42858 1/20 0.50
CYP1A2 P05177 2/20 0.47
CYP2C9 P11712 1/20 0.47
POLB P06746 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.44
GLA P06280 1/20 0.44
CASP1 P29466 1/20 0.44
MEN1 O00255 1/20 0.44
CYP3A4 P08684 1/20 0.44
KMT2A Q03164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6414256 0.86 TSHR (0.51) ALDH1A1MAPTKDM4ETSHRGAA
SCHEMBL6417640 0.79 ALDH1A1 (0.65) ALDH1A1MAPTKDM4ETSHRGAA
SCHEMBL2330855 0.75 ALDH1A1 (0.49) ALDH1A1MAPTKDM4ETSHRGAA
SCHEMBL2336448 0.70 GAA (1.00) ALDH1A1MAPTKDM4ETSHRGAA
SCHEMBL6413221 0.70 CYP1A2 (0.55) ALDH1A1MAPTKDM4ETSHRGAA
SCHEMBL6417623 0.69 MAPT (0.56) ALDH1A1MAPTKDM4ETSHRGAA
SCHEMBL6417898 0.69 ALDH1A1 (0.69) ALDH1A1MAPTKDM4ETSHRGAA
SCHEMBL6413379 0.69 TSHR (0.51) ALDH1A1MAPTKDM4ETSHRGAA
SCHEMBL6413097 0.69 TSHR (0.54) ALDH1A1MAPTKDM4ETSHRGAA
SCHEMBL17317370 0.69 ALDH1A1 (0.65) ALDH1A1MAPTKDM4ETSHRGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050124614-A1 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis AXYS PHARMACEUTICALS, INC. (US) 2005-06-09 US claimed
WO-2004004727-A1 3,4-DIHYDROISOQUINOLIN-1-ONE DERIVATIVES AS INDUCERS OF APOPTOSIS AXYS PHARMACEUTICALS, INC. (US) 2004-01-15 WO claimed
US-20050124614-A1 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis AXYS PHARMACEUTICALS, INC. (US) 2005-06-09 US disclosed
WO-2004004727-A1 3,4-DIHYDROISOQUINOLIN-1-ONE DERIVATIVES AS INDUCERS OF APOPTOSIS AXYS PHARMACEUTICALS, INC. (US) 2004-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124614-A1 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis CASP3, BAX, BAD ALDH1A1 1368/4885MAPT 3291/4885KDM4E 2355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.